The ARHGEF6 Knockout A-549 Polyclonal Cells constitute a CRISPR/Cas9-engineered polyclonal population derived from the human A-549 lung carcinoma cell line, designed to introduce loss-of-function mutations in the ARHGEF6 gene. This product enables studies of Rho guanine nucleotide exchange factor signaling without the need for transient silencing approaches, providing a stable model for investigating ARHGEF6-dependent processes. The polyclonal nature ensures representation of a range of edited alleles, yielding a heterogeneous pool that can be used directly in functional assays.
The A-549 host cell line is an adherent epithelial cell line originally isolated from a 58-year-old male with lung adenocarcinoma. These cells are widely employed as an in vitro model for respiratory epithelium and lung cancer biology, particularly for studies of epithelial-to-mesenchymal transition, migration, and invasion. Their well-characterized genetic background and robust growth make them suitable for genome editing and subsequent cellular analyses.
ARHGEF6 encodes a guanine nucleotide exchange factor that specifically activates the small GTPases RAC1 and CDC42 by catalyzing the exchange of GDP for GTP. These GTPases, in turn, orchestrate actin cytoskeleton dynamics through effectors such as PAK1 and the Arp2/3 complex. Upstream, ARHGEF6 is regulated by integrin receptors, EGFR, and SRC family kinases. It interacts with scaffold proteins including PAK1, PAK2, GIT1, ??-catenin, CASK, and PAR3, linking extracellular cues to lamellipodia and filopodia formation, focal adhesion turnover, and cell adhesion. ARHGEF6 operates within pathways such as RAC1/CDC42 signaling, integrin signaling, cadherin signaling, and axon guidance, ultimately impacting JNK and actin remodeling.
In the context of A-549 cells, ARHGEF6 knockout is anticipated to impair RAC1/CDC42-mediated cytoskeletal reorganization, leading to disrupted lamellipodia protrusion and reduced migratory capacity. Given the lung adenocarcinoma origin, this model is particularly valuable for dissecting the role of Rho GTPase signaling in cancer cell invasion and metastasis. The knockout background helps delineate ARHGEF6-specific contributions to integrin- and EGFR-driven motility, potentially revealing vulnerabilities in the metastatic cascade.
Researchers can employ these polyclonal knockout cells in a variety of experimental settings, including wound healing migration assays, transwell invasion assays, and phalloidin staining for actin visualization. Confirmation of ARHGEF6 disruption can be validated by western blotting and RT-qPCR. Downstream readouts such as RAC1-GTP pulldown assays, phospho-PAK and phospho-JNK immunoblotting, and immunofluorescence for focal adhesion markers enable comprehensive pathway analysis. The product supports drug target validation for Rho GTPase modulators and functional dissection of ARHGEF6 in epithelial cell biology. For further details and technical support, please contact Ascent Research.
